Further issues with new oral anticoagulants

Current Pharmaceutical Design

Volumn 16, Issue 31, 2010, Pages 3487-3489

  Huisman, M V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Heart valves; New anticoagulants; Pregnancy; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APTAMER; DABIGATRAN; EPTIFIBATIDE; HEPARIN; OTAMIXABAN; RB 006; RB 007; RIVAROXABAN; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; CORONARY ARTERY BYPASS GRAFT; DRUG INDICATION; HEART VALVE PROSTHESIS; HUMAN; LOW DRUG DOSE; NEOPLASM; ORTHOPEDIC SURGERY; PERCUTANEOUS CORONARY INTERVENTION; PREGNANCY; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUGS, INVESTIGATIONAL; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; VENOUS THROMBOEMBOLISM;

EID: 78649957260     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563356     Document Type: Article

References (28)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158(6): 585-593.
2. Prandoni P, Lensing AW, Cogo A, et al. The long term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125(1): 1-7.
3. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmo-nary embolism. N Engl J Med 1992; 326(19): 1240-1245.
4. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343(25): 1846-1850.
5. Lee AY, Levine MN, Baker RI, et al. Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146-153.
6. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337(10): 688-698.
7. Schulman S, Kearon C, Kakkar AK, et al. Re-cover study group. Dabigatran versus warfarin in the treatment of acute venous throm-boembolism. N Eng J Med 2009; 361: 2342-2352.
8. Bates SM, Greer I, Pabinger I, Sofaer S, Hirsh J. Venous throm-boembolism, thrombophilia, antithrombotic therapy, and pregnancy. Chest 2008; 133: 844-886.
9. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191-196.
10. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocy-topenia: alternative anticoagulation in pregnancy and lactation. Semin Thromb Haemost 2002; 28: 439-45.
11. Markwardt F, Fink G, Kaiser B, et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988; 43: 202-207.
12. Furlan A, Vianello F, Clementi M, et al. Heparin-induced thrombo-cytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin; a case-report [letter]. Haematologica 2006; 91: 19-20.
13. Dempfle CE. Minor transplacental passage of fondaparinux in vivo [letter]. N Engl J Med 2004; 350: 1914-1915.
14. Harenberg J. Treatment of a woman with lupus and thromboem-bolism and cutaneous intolerance of heparins using fondaparinux during pregnancy [letter]. Thromb Res 2007; 119: 385-388.
15. Mazzolai L, Hohfeld P, Spertini F, et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108: 1569-1570.
16. Rivaroxaban FDA DDAC document. www.fda.gov
17. Guertin KR, Choi YM. The discovery of the factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem 2007; 14: 2471-2481.
18. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active controlled, phase 2 trial. Lancet 2009; 374: 787-795.
19. Rusconi CP, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulationfactor IXa. Nature 2002; 419: 90-94.
20. Dyke CK, Steinhubl SR, Kleiman NS, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490-2497.
21. Chan MY, Cohen MG, Dyke CK, Myles SK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008; 117: 2865-2874
22. Baudet EM, Puel V, McBride JT, et al. Long-term results of valve replacement with the St. Jude Medical prosthesis. J Thorac Cardio-vasc Surg 1995; 109: 858-870
23. Bjork VO, Henze A. Management of thrombo-embolism after aortic valve replacement with the Bjork-Shiley tilting disc valve: medicamental prevention with dicumarol in comparison with dipyridamole-acetylsalicylic acid; surgical treatment of prosthetic thrombosis. Scand J Thorac Cardiovasc Surg 1975; 9: 183-191.
24. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323: 1218-1222.
25. Salem DN, Patrick T, O'Gara PT, Christopher Madias C, Pauker SG. Valvular and structural heart disease. Chest 2008; 133; 593-629.
26. Agnelli G, Sonaglia F, Becattini C. Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. Curr Pharm Des 2005; 11(30): 3885-3891.
27. Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 2008; 14(12): 1152-1175.
28. Francis CW. Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. Curr Pharm Des 2005; 11(30): 3931-3941.